Prothena - Stock Price History | PRTA
Historical daily share price chart and data for Prothena since 2023 adjusted for splits. The latest closing stock price for Prothena as of January 27, 2023 is 57.12.
- The all-time high Prothena stock closing price was 78.89 on September 23, 2021.
- The Prothena 52-week high stock price is 66.47, which is 16.4% above the current share price.
- The Prothena 52-week low stock price is 21.06, which is 63.1% below the current share price.
- The average Prothena stock price for the last 52 weeks is 40.05.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Prothena Historical Annual Stock Price Data |
Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
2022 |
38.8881 |
49.2200 |
65.0000 |
22.7300 |
60.2500 |
21.96% |
2021 |
42.2095 |
12.3000 |
78.8900 |
11.0000 |
49.4000 |
311.32% |
2020 |
11.7699 |
15.6300 |
15.7700 |
7.5400 |
12.0100 |
-24.13% |
2019 |
10.5694 |
10.5000 |
17.0100 |
6.8900 |
15.8300 |
53.69% |
2018 |
20.4841 |
37.8000 |
45.0400 |
8.7300 |
10.3000 |
-72.53% |
2017 |
54.5062 |
49.7900 |
67.7500 |
35.4400 |
37.4900 |
-23.79% |
2016 |
47.9551 |
62.2200 |
67.6400 |
30.1200 |
49.1900 |
-27.78% |
2015 |
46.1863 |
20.3500 |
75.3100 |
19.0500 |
68.1100 |
228.08% |
2014 |
24.7390 |
28.1000 |
48.3000 |
17.2600 |
20.7600 |
-21.72% |
2013 |
14.7389 |
7.0000 |
29.0400 |
5.8400 |
26.5200 |
261.80% |
2012 |
6.9833 |
7.2000 |
7.3300 |
6.8000 |
7.3300 |
0.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$2.702B |
$0.201B |
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
|